Optimal thresholds of early response to atypical antipsychotics: Application of signal detection methods

Schizophrenia Research

Volumn 113, Issue 1, 2009, Pages 34-40

  Chen, Lei ^a   Ascher Svanum, Haya ^a   Stauffer, Virginia ^a   Kinon, Bruce J ^a   Kollack Walker, Sara ^a   Ruberg, Stephen ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Atypical antipsychotics; Early response; Signal detection

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT;

ACCURACY; ADULT; ARTICLE; CLINICAL INDICATOR; CLINICAL TRIAL; CONTROLLED STUDY; DISCRIMINANT VALIDITY; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; HUMAN; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SENSITIVITY AND SPECIFICITY; SIGNAL DETECTION; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; ROC CURVE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SIGNAL DETECTION, PSYCHOLOGICAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 67649876110     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2009.06.001     Document Type: Article

References (25)

1. Agid O., Kapur S., Arenovich T., and Zipursky R.B. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch. Gen. Psychiatry 60 12 (2003) 1228-1235
2. Agid O., Seeman P., and Kapur S. The "delayed onset" of antipsychotic action-an idea whose time has come and gone. J. Psychiatry Neurosci. 31 2 (2006) 93-100
3. Andreasen N.C., Carpenter Jr. W.T., Kane J.M., Lasser R.A., Marder S.R., and Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 162 3 (2005) 441-449
4. Ascher-Svanum H., Nyhuis A.W., Fries D.E., Kinon B.J., Baker R.W., and Shekhar A. Clinical, functional, and economic ramifications of early nonresponse to treatment of schizophrenia, part 1: acute treatment of schizophrenia. World J. Biol. Psychiatry 6 3 (2008) 132-191
5. Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz W.F., and Moller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J. Biol. Psychiatry 7 1 (2006) 5-40
6. Hosmer D.W., and Lemeshow S. Applied Logistic Regression. 2nd Edition (2000), Willey, New York
7. Kaplan H.I., and Sadock B.J. Comprehensive textbook of psychiatry. 12.12: Schizophrenia-Somatic Treatment (pp. 1467); 31.16: Dopamine Receptor Antagonists (pp. 2817) (2005), Lippincott Williams & Wilkins, Baltimore, MD
8. Kay S.R., Opler L.A., and Fjalland B. Positive and Negative Syndrome Scale (PANSS) Manual (1986), Multi-Health Systems, New York North Tonawanda
9. Keefe R.S., Seidman L.J., Christensen B.K., Hamer R.M., Sharma T., Sitskoorn M.M., Rock S.L., Woolson S., Tohen M., Tollefson G.D., Sanger T.M., and Lieberman J.A. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol. Psychiatry 59 2 (2006) 97-105
10. Kinon B.J., Lipkovich I., Edwards S.B., Adams D.H., Ascher-Svanum H., and Siris S.G. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J. Clin. Psychopharmacol. 26 2 (2006) 157-162
11. Kinon B.J., Noordsy D.L., Liu-Seifert H., Gulliver A.H., Ascher-Svanum H., and Kollack-Walker S. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J. Clin. Psychopharmacol. 26 5 (2006) 453-461
12. Kinon B.J., Chen L., Ascher-Svanum H., Stauffer V.L., Kollack-Walker S., Sniadecki J.L., and Kane J.M. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr. Res. 102 1-3 (2008) 230-240
13. Kinon B.J., Volavka J., Stauffer V., Edwards S.E., Liu-Seifert H., Chen L., Adams D.H., Lindenmayer J.P., McEvoy J.P., Buckley P.F., Lieberman J.A., Meltzer H.Y., Wilson D.R., and Citrome L. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J. Clin. Psychopharmacol. 28 4 (2008) 392-400
14. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., and Kreyenbuhl J. Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry 161 Suppl 1 (2004) 1-56
15. Leucht S., Busch R., Hamann J., Kissling W., and Kane J.M. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol. Psychiatry 57 12 (2005) 1543-1549
16. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., and Engel R.R. What does the PANSS mean?. Schizophr. Res. 79 2-3 (2005) 231-238
17. Leucht S., Kane J.M., Etschel E., Kissling W., Hamann J., and Engel R.R. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 31 10 (2006) 2318-2325
18. Leucht S., Busch R., Kissling W., and Kane J.M. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J. Clin. Psychiatry 68 3 (2007) 352-360
19. Leucht S., Shamsi S.A., Busch R., Kissling W., and Kane J.M. Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study. Schizophr. Res. 101 1-3 (2008) 312-319
20. Liu-Seifert H., Adams D.H., and Kinon B.J. Discontinuation of treatment of schizophrenia patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med. 3 (2005) 21
21. Miller A.L., Hall C.S., Buchanan R.W., Buckley P.F., Chiles J.A., Conley R.R., Crismon M.L., Ereshefsky L., Essock S.M., Finnerty M., Marder S.R., Miller D.D., McEvoy J.P., Rush A.J., Saeed S.A., Schooler N.R., Shon S.P., Stroup S., and Tarin-Godoy B. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J. Clin. Psychiatry 65 4 (2004) 500-508
22. Mossman D., and Somoza E. ROC curves, test accuracy, and the description of diagnostic tests. J. Neuropsychiatry Clin. Neurosci. 3 3 (1991) 330-333
23. Overall J.E., and Gorham D.R. The Brief Psychiatric Rating Scale. Psychol. Rep. 10 (1962) 799-812
24. Tran P.V., Hamilton S.H., Kuntz A.J., Potvin J.H., Andersen S.W., Beasley Jr. C., and Tollefson G.D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol. 17 5 (1997) 407-418
25. Youden W.J. Index for rating diagnostic tests. Cancer 3 1 (1950) 32-35